LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Stool Samples Provide Marker for Bowel Disease

By LabMedica International staff writers
Posted on 08 Apr 2014
Image: The SRI 8610C gas chromatograph (Photo courtesy of SRI Instruments).
Image: The SRI 8610C gas chromatograph (Photo courtesy of SRI Instruments).
A novel method for distinguishing different types of bowel disease using the stool samples of patients has been created which is an ideal noninvasive testing method for the diagnosis of gastro-intestinal diseases.

The method works by analyzing the chemical compounds emitted from the samples and could provide cheaper, quicker and more accurate diagnoses, at the point of care, for a group of diseases that have up until recently been very hard to differentiate.

Scientists at the University of the West of England (Bristol, UK) obtained 182 stool samples from patients with inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) between October 2010 and October 2011. IBS samples were obtained from patients with diarrhea predominant (IBS-D), constipation predominant (IBS-C), and the alternating between the two syndrome (IBS-A). IBD samples were obtained from patients with both ulcerative colitis (UC) and Crohn's disease (CD). Control samples were collected from healthy patients.

The test was based on the volatile organic compounds (VOCs) emitted from their stool samples, which act as a proxy for conditions in the gastrointestinal tract and provide a unique profile, or fingerprint, for the different bowel diseases. The investigators developed the method using an SRI 8610C gas chromatograph (SRI Instruments, Torrance, CA, USA) coupled to a metal oxide sensor system with pattern recognition software.

The results showed that patients with IBD could be distinguished from healthy controls with an accuracy of 79%. The method was able to distinguish IBD from IBS with an accuracy of 76%. Differentiating patients with IBS from healthy controls using VOCs appeared to be more difficult and could only be achieved with an accuracy of 54%. The reasons could be because IBS is a functional disorder as opposed to a structural disorder, so the changes in composition of VOCs in the stool samples would not be as great, producing a very similar pattern to healthy controls.

In conclusion, the authors stated that: “Our work has demonstrated that a low-cost device based on VOC analysis could be used to potentially diagnose, and differentiate, IBS and IBD at the point of care. We will continue to study fecal volatiles as a way of detecting IBS, IBD and other gastrointestinal conditions and continue to develop our techniques further. If we're able to produce results that exceed current commercial methods, then our technique could be added to the growing number of medical tests that use VOC analysis as a diagnostic tool.” The study was published on March 27, 2014, in the Journal of Breath Research.

Related Links:

University of the West of England 
SRI Instruments 


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Serological Pipet Controller
PIPETBOY GENIUS
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B
New
Staining Management Software
DakoLink

DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
PURITAN MEDICAL